Device Infx-8000c

Interventional Angiography System

Payments companies reported to CMS as associated with Interventional Angiography System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$202Kassociated payments (2023-2025)
398clinicians with associated payments
2companies reporting

By year

2023 $46K
2024 $59K
2025 $96K

Payments reported as associated with Interventional Angiography System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Interventional Cardiology $42K
Thoracic Surgery (Cardiothoracic Vascular Surgery) $27K
Pediatric Cardiology $22K
Vascular & Interventional Radiology $22K
Diagnostic Radiology $21K
Neurological Surgery $18K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Interventional Angiography System

These are the largest totals companies reported as associated with Interventional Angiography System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Kenneth Mattox Houston, TX Thoracic Surgery (Cardiothoracic Vascular Surgery) $27,000.00
Daniel Gruenstein Chicago, IL Pediatric Cardiology $15,000.00
Adnan Siddiqui Williamsville, NY Neurological Surgery $12,571.31
Brian Schuler York, PA Clinical Cardiac Electrophysiology $12,486.28
Salman Arain Houston, TX Interventional Cardiology $11,376.23
Osmanuddin Ahmed Chicago, IL Diagnostic Radiology $6,373.59
Issam Moussa Urbana, IL Interventional Cardiology $5,421.52
Stewart Benton York, PA Interventional Cardiology $5,000.00
Bulent Arslan Chicago, IL Vascular & Interventional Radiology $4,609.33
Barry Bertolet Tupelo, MS Cardiovascular Disease $4,023.63

Prescribed Interventional Angiography System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.